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Abstract
Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of
autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead
to liver failure. Affected individuals are usually in their fifth to seventh decades of life at time of
diagnosis, and 90% are women. Annual incidence is estimated between 0.7 and 49 cases per million-
population and prevalence between 6.7 and 940 cases per million-population (depending on age and
sex). The majority of patients are asymptomatic at diagnosis, however, some patients present with
symptoms of fatigue and/or pruritus. Patients may even present with ascites, hepatic
encephalopathy and/or esophageal variceal hemorrhage. PBC is associated with other autoimmune
diseases such as Sjogren's syndrome, scleroderma, Raynaud's phenomenon and CREST syndrome
and is regarded as an organ specific autoimmune disease. Genetic susceptibility as a predisposing
factor for PBC has been suggested. Environmental factors may have potential causative role
(infection, chemicals, smoking). Diagnosis is based on a combination of clinical features, abnormal
liver biochemical pattern in a cholestatic picture persisting for more than six months and presence
of detectable antimitochondrial antibodies (AMA) in serum. All AMA negative patients with
cholestatic liver disease should be carefully evaluated with cholangiography and liver biopsy.
Ursodeoxycholic acid (UDCA) is the only currently known medication that can slow the disease
progression. Patients, particularly those who start UDCA treatment at early-stage disease and who
respond in terms of improvement of the liver biochemistry, have a good prognosis. Liver
transplantation is usually an option for patients with liver failure and the outcome is 70% survival
at 7 years. Recently, animal models have been discovered that may provide a new insight into the
pathogenesis of this disease and facilitate appreciation for novel treatment in PBC.
Disease name
Primary biliary cirrhosis (PBC)
Definition/diagnostic criteria
Primary biliary cirrhosis (PBC) is a chronic, slowly pro-
gressive, autoimmune, cholestatic liver disease that affects
predominantly middle-aged women [1]. Diagnosis can be
typically established by the triad: antimitochondrial anti-
bodies (AMA) in serum, cholestatic indices and liver his-
tology diagnostic or compatible with PBC.
Addison and Gull have first described PBC in 1851 [2].
The label 'Primary biliary cirrhosis' was adopted in 1949,
even though not all patients were cirrhotic at diagnosis
[3]. The description of 'Chronic non-suppurative destruc-
tive cholangitis' [4], a more appropriate term for the dis-
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ease, suffers from being too long and thus has never been
adopted.
Epidemiology
Patients usually present in the fifth to seventh decade and
PBC is rarely diagnosed in teenagers [5]. PBC have a
female predominance with an 8:1 female-to-male ratio
[6]. PBC affects individuals of all ethnic origin and
accounts for 0.6~2.0% of deaths from cirrhosis worldwide
[7]. Its prevalence is estimated to be between 6.7 and 940
cases per million-population (the latter in women >40 yrs
old in United Kingdom), while its incidence is estimated
to be between 0.7 and 49 cases per million-population per
year [8-15]. The highest incidence and prevalence rates
come from the United Kingdom [8,15], Scandinavia [9],
Canada [10,11] and the United States [12,13], all in the
northern hemisphere, whereas the lowest is from Aus-
tralia [14]. There is no clear worldwide evidence to sup-
port the concept of "a polar-equatorial gradient" as it has
been reported for other autoimmune conditions [16], but
it may also be the case in PBC.
Clinical description and diagnostic methods
The diagnosis of PBC is based on a combination of clini-
cal features, an abnormal liver biochemical pattern (a
cholestatic picture with or without a hepatitis picture) per-
sisting for more than six months and the presence of
detectable AMA in serum. The diagnosis may be con-
firmed by finding characteristic histological features. A
"probable" diagnosis requires the presence of two of these
three criteria, and a "definite" diagnosis requires all three.
The diagnosis of PBC is now made more often and earlier
in the course of the disease than it used to be [17,18],
likely due to the widespread use of AMA testing and the
performance of biochemical screening in healthy individ-
uals [19]. AMA is negative in approximately 10% of
patients who otherwise have all the features typical of PBC
[20]. All AMA negative patients with cholestatic liver dis-
ease should be carefully evaluated for the presence of PBC
by cholangiography as well as liver biopsy.
Clinical features
PBC is a chronic liver disease generally characterized by a
slow progression but a highly variable clinical course.
More than half of patients diagnosed today are asympto-
matic at diagnosis [21,22]. They are generally identified
by finding of an elevation of only serum alkaline phos-
phatase (ALP) or/and total serum cholesterol, often by
chance through routine check up. The diagnosis may also
be made in patients undergoing further investigation for
an associated autoimmune disease such as scleroderma. It
may take years before asymptomatic subjects develop
symptoms of the disease. But asymptomatic disease is not
synonymous with early liver disease. Little is known about
why some patients remain asymptomatic and other
progress rapidly and develop liver failure. The severity of
the liver disease may be discordant with the severity of
symptoms. In symptomatic patients, fatigue and pruritus
are the most common presenting complaints [10].
Patients with cirrhosis may present with ascites, hepatic
encephalopathy and/or esophageal variceal hemorrhage.
However, variceal hemorrhage is not limited to those with
cirrhosis, as presinusoidal portal hypertension due to
nodular regenerative hyperplasia (NRH) of the liver is
sometimes present [23]. Once jaundice is present, fat-sol-
uble vitamin deficiency and malabsorption (e.g.: steator-
rhea and weight loss) may occur.
The prevalence of fatigue has been reported to be as high
as 80% [24]. Fatigue does not correlate with the liver dis-
ease severity [25] and liver transplantation does not
improve fatigue [26].
Pruritus, when present, may be a debilitating symptom
that significantly impairs quality of life in PBC, just as may
fatigue. Usually, pruritus occurs months to years earlier
than jaundice, and may improve with progression of liver
disease! It is usually less severe in sunny weather and,
being worse at night, it may interfere with sleep. Severe
pruritus causes sleep deprivation and may even lead to
suicidal ideation [27]. Sometimes PBC is initially diag-
nosed during pregnancy prompted by the symptom of
pruritus that fails to disappear in the post partum period,
unlike intrahepatic cholestasis of pregnancy.
Approximately 10% of patients complain of vague inter-
mittent right upper quadrant pain or discomfort, which
usually resolves spontaneously [28].
Physical examination
Physical examination may be normal in those with early-
stage disease. As the disease progresses, patients may
develop signs of portal hypertension such as splenomeg-
aly and collateral vessels, and features of cholestasis such
as skin pigmentation due to increased melanin deposition
in the skin. In late stage disease, when both liver and
spleen are enlarged, signs of liver failure such as ascites
and encephalopathy are seen [22]. However, there is no
specific dermatological feature in PBC patients with pruri-
tus other than diffuse pigmentation and scratch marks.
Xanthelasma are seen in a minority of patients and xan-
thomas are rare nowadays, despite PBC related hypercho-
lesterolemia being present. Signs and symptoms of
scleroderma, particularly affecting the hands and swal-
lowing, may be present.
Laboratory tests
Serum ALP and gamma-glutamyl transpeptidase (GGT)
are raised and serum aminotransferase can also be ele-
vated [29]. Serum AMA are detected in more than 90% ofOrphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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affected individuals [20]. Elevated levels of immunoglob-
ulin M are common in PBC [30,31]. Titer of AMA does not
carry any clinical significance nor do AMA profiles [32].
Although rare findings in patients with PBC, "nuclear-
rim" and "multiple nuclear-dot" patterns are highly spe-
cific for PBC irrespective of AMA status, and may provide
supportive evidence for PBC especially in those who test
AMA negative [33]. Liver synthetic function, i.e.: changes
in albumin and prothrombin time (PT) are observed with
disease progression. But hyperbilirubinemia may be
present earlier due to the cholestatic nature of this disease.
Imaging
Lymphadenopathy in the abdomen is seen in 80% of
patients with PBC [34]. There is no specific feature on
abdominal images in PBC although the intraabdominal
lymph nodes may be so large as to suggest lymphoma.
Abdominal images are not necessary to confirm the diag-
nosis of PBC in patients who test positive for AMA. How-
ever, those patients who are AMA negative and thought to
nevertheless have PBC need radiographic demonstration
of a normal biliary tree on cholangiography, either by
magnetic resonance cholangiopancreatography (MRCP)
or endoscopic retrograde cholangiopancreatography
(ERCP), to exclude other possible diagnoses, particularly
primary sclerosing cholangitis (PSC). Findings from
abdominal images in advanced PBC often resemble those
seen in other forms of cirrhosis, with a heterogeneously
attenuating liver, varices and splenomegaly.
Histology
The characteristic lesion of PBC is the asymmetric destruc-
tion of the intralobular bile ducts within portal triads.
Histological staging systems of PBC have been proposed
and they have been divided into 3 or 4 distinct stages,
according to the degree of fibrosis, inflammation and/or
bile duct damage [4,35-37]. According to the Ludwig's
classification [37], stage 1 is defined by portal inflamma-
tion. Stage 2 is extension of this inflammation beyond
portal tracts into the surrounding parenchyma, with or
without associated duct loss. In stage 3, fibrous septa link
adjacent portal triads. Stage 4 represents cirrhosis. On the
other hand, with Scheuer's system [35], stage 1 is referred
to as the florid duct lesion or chronic non-suppurative
destructive cholangitis (Figure 1). In stage 2, there is pro-
liferation of the small bile ductules (Figure 2). Stage 3 is
characterized by fibrosis or scarring. Stage 4 is cirrhosis.
However, the entire liver is not always uniformly
involved, and a single biopsy may demonstrate the feature
of all four stages simultaneously. Thus both under- and
over-estimation may occur. It is crucial to have a sufficient
size of specimen to minimize error [38]. There should be
a minimum of 10 portal tracts visualized before a confi-
dent diagnosis of bile duct loss can be established.
Although liver biopsy is not always necessary to make a
diagnosis of PBC, it does allow the severity of disease to
be clarified. It also may indicate the need of specific ther-
apeutic regimens or management (such as ultrasound
screening for hepatocellular carcinoma, HCC, in PBC
patients found to be cirrhotic) and, additionally, may be
used as an objective way for evaluating the response to
treatment.
Primary biliary cirrhosis, showing ductular proliferation  (stage 2 of Scheuer's classification) Figure 2
Primary biliary cirrhosis, showing ductular proliferation 
(stage 2 of Scheuer's classification). Small ductular structures 
(arrow) is shown in a portal tract (asterisk). (Hematoxylin-
eosin.)
*
Primary biliary cirrhosis, demonstrating chronic non-suppu- rative destructive cholangitis (stage 1 of Scheuer's classifica- tion) Figure 1
Primary biliary cirrhosis, demonstrating chronic non-suppu-
rative destructive cholangitis (stage 1 of Scheuer's classifica-
tion). Infiltration of lymphocyte (arrow) and plasma cell (bold 
arrow) into bile duct is shown. (D-PAS.)Orphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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Associated diseases (Table 1)
Associations between PBC and other autoimmune dis-
eases have been reported. In an older report of extrahe-
patic autoimmune diseases among patients with PBC,
84% and 41% of the patients had at least one and more
than two associated autoimmune disease, respectively, in
addition to PBC. Sjögren syndrome, including sicca syn-
drome was the most commonly associated autoimmune
disease, seen in 66% of the patients [39]. However, this
report was not a population-based study, thus, their true
extent and pattern was unknown. Recently, a population-
based cohort study has shown the greatest relative
increase in disease prevalence for scleroderma (8% of
patients); 53% of patients had at least one associated
autoimmune disease. The risk of Sjögren syndrome and
Raynaud's phenomenon was about 4-fold higher than
unaffected controls. The significance of systemic lupus
erythematosus (SLE) as a risk factor for PBC was also con-
firmed. In this report, AMA negative patients had a signif-
icantly higher prevalence of additional autoimmune
condition than AMA positive patients (79% vs. 49%) [40].
In patients with PBC and/or CREST syndrome, overrepre-
sentation of a T-cell receptor beta chain variable region
(TCRBV3) was documented, suggesting a distinct disorder
[41]. These associations further support the hypothesis of
genetic susceptibility as a predisposing factor for PBC.
Differential diagnosis (Figure 3)
In 2007, the majority of patients with PBC present with-
out symptoms, most are identified with abnormal liver
enzymes at the time of a regular check up or during work
up for another disease. It is not difficult to diagnose PBC
when the patients have typical features, particularly AMA
positivity. However, 0.5% of people in general population
are also positive for AMA [42]. As obesity and non-alco-
holic fatty liver disease (NAFLD) is becoming a serious
issue worldwide, abnormal liver biochemical tests are not
unusual in the general population. These factors all have
to be taken into account in the differential diagnosis,
especially when patients with abnormal liver enzymes are
of a 'cholestatic nature', not unusual in NAFLD or drug
induced liver injury.
All AMA negative patients with cholestatic liver disease
should be carefully evaluated. In the differential diagno-
sis, the initial step is to clarify if the site of the damage is
extra-hepatic, intra-hepatic or both. In addition to a care-
fully taken history, ultrasound (US) may help to differen-
tiate these conditions. If abnormalities of the biliary tree
are seen on US, cholangiography (MRCP) will help fur-
ther differentiation, particularly in the diagnosis of PSC.
The typical bile duct irregularities of PSC are demon-
strated on cholangiography, but in early PSC as well as
small duct PSC, the biliary tree may appear normal.
Cholangiography may also help in the diagnosis of other
bile duct lesions such as stones, cyst or tumor that may be
not visualized on US [43]. If the extra-hepatic biliary sys-
tem appears normal, then liver biopsy is required. Liver
biopsy allows differentiation between cholestatic disease
(generally a "vanishing bile duct syndrome") and an infil-
tration in the liver, i.e.: lymphoma.
Secondary biliary cirrhosis is a biliary cirrhosis that devel-
ops secondary to a pathogenic process or injury of known
cause (just as is the case for secondary sclerosing cholan-
gitis [44]) and may occur with chronic biliary obstruction
of any cause (eg. hepatolithiasis or cystic fibrosis) [45].
It is also important to note that a possible change in diag-
nosis should continue to be considered during follow-up
as well as at the time of initial diagnosis. Fatty liver and
drug induced liver injury are the most common comor-
bidities that may "interfere" with the initial diagnosis or
during follow up. These should be always considered if a
Table 1: Diseases or disorders associated with PBC
Sjögren's syndrome (Sicca syndrome)
Scleroderma
Raynaud's disease
CREST syndrome
Calcinosis cutis
Raynaud's phenomenon
Esophageal dysmotility
Sclerodactyly
Telangiectases
Systemic lupus erythematosus
Rheumatoid arthritis
Mixed connective tissue disease
Polymyositis
Cutaneous disorders
Dermatomyositis
Lichen planus
Pemphigoid
Psoriasis
Autoimmune thrombocytopenic 
purpura
Pernicious anemia
Sarcoidosis
Myasthenia gravis
Autoimmune thyroid disease
Chronic thyroiditis 
(Hashimoto's disease)
Grave's disease (Basedow's 
disease)
Diabetes Type 1 (Insulin-dependent 
diabetes mellitus)
Addison's disease
Inflammatory bowel diseases
Celiac disease
Ulcerative colitis
Crohn's disease
Gallstones
Pulmonary fibrosis
GlomerulonephritisOrphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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patient with PBC has a sudden change in the liver enzyme
pattern. Autoimmune hepatitis (AIH) is another disease
that may develop subsequently [46], thus, it also should
be considered in the differential diagnosis, particularly
with a transaminitis. The most reliable feature to suggest
development of AIH would be a further rise in serum IgG.
Similarly, a co-existent untreated celiac disease (present in
7% of patients with PBC, particularly in Caucasians) may
cause an increase in liver enzymes or a failure to normal-
ize with UDCA [47]. A recent general population-based
study from Sweden has shown that odds ratio of PBC and
fatty liver in celiac disease is 15.0 and 5.83, respectively
[48]. The anti-transglutaminase antibody test is specific
and highly diagnostic for celiac disease. There are reports
of improvement of liver enzymes or even reversal of
hepatic failure after introducing gluten free diet in
patients with PBC associated with celiac disease [49]. Thy-
rotoxicosis may lead to the sudden onset of jaundice [50].
Etiology
Genetic factors
Familial predisposition to PBC is not rare, its prevalence
rate among first-degree relatives has been estimated to be
approximately 5% [51], which is more common than in
unrelated persons. It has been reported that familial PBC
is related to maternally inherited factors, and that the dis-
ease tends to present earlier in the second generation [52],
and is most common in mother-daughter and sister-sister
combinations [53]. Familial cohort studies have shown
that the concordance rate of PBC in monozygotic twins
was 63% versus  0% among dizygotic twins. Among
monozygotic twins, the age of disease onset was similar,
but there were differences in the natural history and dis-
ease severity, emphasizing the role of epigenetic factors or
simply environmental factors [54]. Although the disease
is virtually identical in women and men, recent data sug-
gest that X-chromosome monosomy in lymphoid cells is
common in women with PBC [55]. Genes governing
immune tolerance are carried on the X gene. Case reports
of PBC in patients with Turner syndrome also support the
Diagnosis of PBC Figure 3
Diagnosis of PBC. Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; AMA, antimitochondrial antibody; CT, 
computed tomography; GGT, gamma-glutamyl transpeptidase; IHBD, intrahepatic bile duct; MRCP, magnetic resonance 
cholangiopancreatography; MRI, magnetic resonance imaging; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangi-
tis; SSC, secondary sclerosing cholangitis; VBDS, vanishing bile duct syndrome.
Abnormal ALP
Drug history Discontinue and observe
Ultrasound
Dilated bile duct(s) Normal bile ducts
AMA positive
Biopsy
Probable PBC
PBC Normal
MRCP
Cholestasis
Small duct PSC
VBDS
Stricture
PSC
SSC
Biopsy
Focal lesion CT or/and MRI
* Infiltration into the liver
e.g.: Malignant lymphoma
Abnormal GGT or/and Total Bilirubin or/and Total Cholesterol
Confirmation ALP of liver origin
Rule out drug history
IHBD stone Liver neoplasm
Pattern suggestive of infiltration
Biopsy
yes
no
Confirmation of disease 
and histological stage
Biopsy *
Occasional 
AIH
Definite PBC
Probable PBC
AMA negativeOrphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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possible role of genes on the X chromosome in the genetic
predisposition to PBC [56].
Infection
Several environmental factors have been suggested as
potential causative initial agents, particularly bacteria.
Escherichia coli and their "rough" mutant have been
reported in excess in the stools of patients with PBC; in
addition, the incidence of urinary tract infections is high
in PBC patients [57,58]. Recently, Novosphingobium aro-
maticivorans, a ubiquitous organism that metabolizes
organic compounds and estrogens, has been proposed as
a candidate for the induction of PBC [59]. The titers of
antibody against the lipoylated bacterial proteins of N.
aromaticivorans were 1,000-fold higher than those to E.
coli, in patients with PBC including patients in early stage
of disease.
Various other bacteria, such as Chlamydia pneumoniae,
Helicobacter pylori and Mycobacterium gordonae have also
been implicated as putative pathogens [60-63]. However,
no compelling data have been provided to show that any
individual agent can be reproducibly detected in the liver
of patients with PBC [64].
Recently, it has been reported that human betaretrovirus
(that shares marked genetic homology with the mouse
mammary tumor virus) infection may be detected in
approximately 75% of patients with PBC (by reverse tran-
scription polymerase chain reaction and immunochemis-
try) [65]. This has been supported by histological and
biochemical endpoints achieved in a pilot study of an
antiretroviral agent [66]. However, other studies have not
been able to reproduce these data [67].
Past surgery
Surgeries including appendectomy, other abdominal sur-
geries and tonsillectomy are significantly increased in
patients with PBC in an epidemiological study in North
America [68]. However, an earlier population-based case-
control study conducted in England did not show any
association with surgical procedures [69]. More recently, a
case-control study provided evidence that there was no
association between PBC and the occurrence of appendec-
tomy, and pointed out the selection bias present in the
previous study done in North America [70]. However, the
observation of a PBC-specific immune response to the
highly conserved caseinolytic protease P of Yersinia entero-
colitica in 40% of patients with PBC may support the link
with past appendenctomy [71], where infection with Y.
enterocolitica is one of the major causes of acute terminal
ileitis mimicking acute appendicitis [72].
Environmental chemicals
A recent experiment demonstrated that circulating anti-
bodies isolated from the serum of PBC patients recog-
nized artificially altered (by environmental chemicals) the
lipoic acid component of the pyruvate dehydrogenase
complex (PDC) epitope [73]. This same group of investi-
gators has shown that 2-octynoic acid, which is widely
used in the manufacture of perfumes, lipstick and many
common food flavorings, have the potential to modify E2
subunit of PDC (PDC-E2) in vivo [74]. The frequent use of
nail polish has been linked to risk of having PBC [75].
Smoking has been demonstrated to accelerate the progres-
sion of PBC and to be a risk factor for PBC [75,76], possi-
bly due to exposure to chemicals in cigarette smoke.
Apparent clusters of populations and a group of individu-
als living close to toxic waste or specific reservoirs have
been reported to have higher rate of incidence or preva-
lence of PBC and this suggests toxic waste as a risk factor
or trigger of the disease [77-79].
Pathogenesis
Immune mediated destruction of bile duct epithelial cells
is thought to drive the pathogenesis of PBC. Although the
exact mechanism underlying the pathogenesis of PBC
remains uncertain, PBC is regarded as an organ specific
autoimmune disease. The hallmark of autoimmune proc-
ess is the detection of AMA in serum, although a recent
study indicates that AMA are detectable, absent transiently
in fulminant liver failure [80]. AMA targets three compo-
nents of M2 family of mitochondrial antigens: the PDC-
E2, the 2-oxoglutarate dehydrogenase complex (OGDC)
and branched-chain 2 oxo-acid dehydrogenase complex
(BCOADC). Of these three, the major autoepitope recog-
nized by both T and B cells is the inner lipoyl domain of
the PDC-E2 [81]. PDC is a member of the 2-oxo-acid
dehydrogenase family of multi-enzyme complexes and is
associated with both cellular and humoral immune
responses in PBC.
Autoantibodies to nuclear antigens can be detected in the
serum in approximately 50% of patients with PBC, who
often have AMA. These antigens include gp210, p62 and
lamin B receptor that are nuclear pore proteins, and sp100
that is nuclear body protein. It has been shown that indi-
viduals who have sustained antibody response to gp210
antigen in the sera [82] or a high expression of gp210 anti-
gen in small bile ducts in liver tissue [83], are at higher risk
of progression to end-stage hepatic failure.
It remains a mystery how PDC-E2 and other epitopes
localized to the inner membrane of mitochondria become
a targets of autoimmune injury in such highly selective
biliary epithelial cells and salivary duct cells [84]. It has
been suggested that apoptosis can increase the exposure of
PDC-E2 to the immune system, leading to an autoim-Orphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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mune attack. It has been postulated that apoptotic cholan-
giocytes, unlike other apoptotic cell types, are a potential
source of immunogenic PDC-E2 in patients with PBC
[85]. Sera from patients with PBC have been found to
have antibodies to environmental toxins thought suffi-
cient to break self-tolerance [74]. Down regulation of the
anti-apoptotic protein, bcl-2 family, in injured portal
tracts has been demonstrated to be a marker of ongoing
apoptosis of cholangiocytes [85,86].
Patients with PBC are usually characterized by the pres-
ence of PDC-E2-specific CD4 and CD8 positive T cells in
the sera [87] and PDC-specific T cells in the liver [88],
mostly during early phase of the disease. Recently, a CD8
positive T cell epitope of PDC-E2 (amino acid 159–167),
has been identified [89] and HLADR4*0101-restricted
CD8 positive T cells from livers of patients with PBC have
demonstrated cytotoxicity against PDC-E2 (amino acid
159–167) pulsed autologous cells [90]. These findings
strongly suggest a contribution by T-cell mitochondrial
responses in the bile duct injury of PBC.
A mouse model of NOD.c3c4 mice congenitally derived
from a non-obese diabetic strain recently described devel-
ops an autoimmune biliary disease and tests AMA positive
[91]. Two other animal models, IL-2 receptor alpha (-/-)
mice and TGF-beta receptor II dominant-negative mice
also show an association with AMA and chronic biliary
disease [92,93]. The affected biliary epithelium is infil-
trated with CD4 positive and CD8 positive T cells in all of
these models. However, granulomas and eosinophilic
infiltration are seen only in NOD.c3c4 mice. Whether
these mouse models will facilitate understanding the
pathogenesis of PBC in human is unknown.
Chronic inflammation and repeated injury to small bile
ducts triggers proliferation of bile ductular cells and fibro-
sis caused by adjacent myofibroblastic cells in the hepatic
mesenchyme. Fibro-proliferative bile ductular cells often
extend into the hepatic parenchyma, bridging adjacent
portal areas and leading to biliary cirrhosis without
renewal of bile ducts [94]. The pathogenesis of the fibro-
genic response to bile duct injury has been recently inves-
tigated with a new concept the "Hedgehog pathway" in
the liver, which is a system that regulates the viability and
differentiation of various progenitors during embryogen-
esis [95]. The Hedgehog pathway has recently been shown
to promote the growth of both biliary epithelial cells and
stromal cells, where signaling between them may modu-
late the mechanism of bile duct injury [96]. The proximity
of the myofibroblasts and cholangiocytes suggests that
mesenchymal-epithelial crosstalk promotes the fibro-pro-
liferative response to cholestatic liver injury via the Hedge-
hog pathway [97].
Treatment for underlying disease
Three groups of drugs have been evaluated in PBC: immu-
nomodulators, antifibrotics and anticholestatics. Cur-
rently, the first-line therapy is ursodeoxycholic acid
(UDCA), an anticholestatic [98].
Ursodeoxycholic acid (UDCA)
UDCA is a bile acid, which naturally comprises 2% of
human bile. Treatment with UDCA improves serum
biomarkers such as bilirubin, ALP, GGT, alanine ami-
notransferase, aspartate aminotransferase, cholesterol and
IgM levels [99-101].
According to the combined data from three controlled tri-
als, UDCA between 13 and 15 mg/kg body weight is con-
sidered the preferred treatment for PBC [102]. It is safe
and the side effects are few. Some patients suffer from hair
thinning, gain in weight and/or diarrhea. Significant
weight gain that occurs in the first 12 months of treatment
persists for the duration of treatment and occurs inde-
pendent of baseline body mass index (BMI) [103].
UDCA improves 10-year survival [104] and/or delays the
progression of hepatic fibrosis in early-stage disease [105],
and the development of esophageal varices in patients
with PBC [106]. Recently, the Spanish group has shown
that a good biochemical response to UDCA (defined by
an alkaline phosphatase decrease greater than 40% of
baseline values or to normal levels) within 1 year of start-
ing treatment is associated with a similar survival to a
matched Spanish control populations but this is not so for
those patients who show no biochemical response follow-
ing introduction of UDCA [107]. However, these findings
are not seen in patients with advanced stage disease at
baseline. Non-randomized controlled studies from
Greece and the Netherlands indicate that in most patients
with PBC (particularly those who are in early stage of dis-
ease), the 10-year survival is comparable to that in the
general population [108,109].
A recent meta-analysis has shown that long-term treat-
ment with mid-dose UDCA (10–20 mg/kg/day) improves
the liver biochemistry and survival free of liver transplan-
tation, and delays histological progression in the early-
stage patients [110]. But whether there is a survival benefit
of treatment with UDCA in PBC still remains controver-
sial. The most recent meta-analysis from Cochrane group
included 6 trials of short duration, some of them non-ran-
domized studies, and there were some data collection
errors with varying doses of UDCA. Thus, their results sug-
gesting no survival benefit with UDCA treatment need to
be questioned [111].
There is no data indicating that UDCA is teratogenic but if
a pregnancy can be planned then it may be wise to stopOrphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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any medication before and during the first trimester.
UDCA is used to treat intrahepatic cholestasis of preg-
nancy [112] and has not been shown to be toxic to the
fetus if given during the second or third trimester.
Other medications
Budesonide (a glucocorticoid with high receptor activity
and high first-pass metabolism in liver) combined with
UDCA has been shown to improve liver histology in 2–3
years in a patient population with or without failure of
UDCA monotherapy [113,114]. Rautiainen et al. have
shown that the plasma concentrations of budesonide do
not differ when the patients were randomized to receive
either budesonide and UDCA, or budesonide alone for 3
years, at least in early PBC [115]. But the combination of
budesonide and UDCA has been shown to be associated
with decreased bone mass density in the femoral neck and
lumbar spine in some patients (probably those with cir-
rhosis) [116]. This combination therapy is promising but
the observation period for side effects is too short at
present, thus, studies with longer follow-up using a com-
bination of budesonide and UDCA are necessary to con-
firm that the benefit outweighs the risks.
Various adjuvant medications have been used alone or in
combination with UDCA in PBC, particularly in patients
with an incomplete response to UDCA monotherapy.
These include systemic corticosteroids [117], azathioprine
[118], cyclosporine [119], mycophenolate mofetil [120],
methotrexate [121], chlorambucil [122], penicillamine
[123], colchicine [124], silymarin [125] and bezafibrate
[126]. Some of the studies have shown a benefit in terms
of improving biochemical markers, decreasing the inten-
sity of pruritus, improving liver histology, reducing the
incidence of major complications of cirrhosis and delay-
ing the need for liver transplantation. However, neither
the large trials nor the pilot studies have indicated any sur-
vival benefit from these additional agents.
Liver transplantation
PBC used to be a common indication for liver transplan-
tation in adults. However, the proportion of patients with
PBC who undergo liver transplantation has recently
decreased, most probably because of the marked increase
of transplantation for cirrhosis due to viral hepatitis, alco-
holic liver disease and HCC. The assessment for liver
transplantation in PBC is indicated when the patients
show features of end-stage liver failure such as profound
jaundice with or without intractable ascites, episodes of
spontaneous bacterial peritonitis, and/or encephalopathy
resistant to appropriate treatment, i.e.  situations with
expected survival less than 1 year. The Mayo Risk Score,
which calculates 2-year survival rate is useful in this
regard. Even though this calculation was developed before
UDCA treatment was introduced, it appears valid even
when UDCA is used [127].
Recently, the MELD (model for end-stage liver disease)
score has been found helpful to decide organ allocation of
patients who are already on the waiting list. The score
includes bilirubin, creatinine and INR (international nor-
malized ratio). The height of the serum bilirubin level
alone is a very important factor when considering the
appropriate timing of referral for liver transplantation
assessment for patients with PBC. One study has shown
that patients should be referred when their serum
bilirubin level reaches to 100 μmol/l (5.9 mg/dl) and that
the outcome post transplantation is better than without
transplantation when the serum bilirubin level is less than
170 μmol/l (10 mg/dl) [128]. The 5-year survival rate after
orthotopic liver transplantation (OLT) in PBC may be as
high as 85%, one of the best outcomes of any liver dis-
eases.
PBC recurs post-OLT in about 20% of patients, usually
between 3 and 7 years post-OLT [129-131]. There is no
correlation between AMA titer and clinical or histological
recurrence of PBC post-OLT. The hallmark feature of
recurrence is granulomatous bile duct destruction seen on
liver biopsy. A plasma cell infiltrate also characterizes
recurrent PBC and distinguishes it from other processes
such as drug induced liver injury and acute or chronic
rejection [132]. Optimal immunosuppression needs to be
provided to prevent recurrence of PBC. It is still controver-
sial as to whether to use cyclosporine or tacrolimus
[131,132]. Disease progression after recurrence is slow
and retransplantation is rarely necessary. However, there
is a report of graft failure due to recurrent disease [133].
Treatment for overlap syndrome between PBC 
and autoimmune hepatitis (AIH)
It has been reported that 12–20% of patients have "over-
lapping" features of PBC and AIH [134,135]. These fea-
tures may present simultaneously but sometimes features
of AIH develop acutely and change the overall pattern of
the liver disease [46]. Corticosteroids are usually contrain-
dicated in PBC because they enhance osteoporosis [117],
though their use is advocated by some authors for these
patients. Features of AIH in PBC may be transient and
response to UDCA therapy similar to patients with PBC
without features of AIH. [136]. However, a recent pilot
study of a long-term outcome suggests that combination
of UDCA and corticosteroids may be the best therapeutic
option for a strictly defined PBC-AIH overlap syndrome
[137].
Patients with AMA negative PBC often test positive for
high titer ANA and have higher levels of IgG [138] but
liver histology indicates no evidence of features of AIH.Orphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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However, a small study of HLA typing in AMA positive
and negative PBC indicated a lack of DR8 in those AMA
negative cases [139].
Complications of PBC and their management 
(Table 2, 3)
Pruritus
Very recent meta-analysis has shown that there are insuf-
ficient data to evaluate the efficacy of cholestyramine
[140]. However, the first choice in the treatment of pruri-
tus in cholestatic patients is cholestyramine (4–12 g/d)
because it is safe. This agent seems to bind bile that con-
tains the unknown pruritogen of cholestasis in the gas-
trointestinal tract. Usually it is helpful and effective when
taken properly, i.e. at the time gallbladder empties (thus it
should be taken before and after breakfast). It also has to
be taken 4 hours apart from any other medications to
avoid their binding. Patients need to appreciate that
cholestyramine should be used for long-term prevention
of pruritus. It may cause abdominal bloating and consti-
pation.
Rifampin would be the second choice when cholesty-
ramine is not effective, starting at 150 mg twice daily. Usu-
ally, its benefit is appreciated in the first week to month of
treatment and increasing the dose may help further in
those patients who initially fail to respond. A recent meta-
analysis indicates that treatment with rifampin leads to
complete or partial resolution of pruritus in 77% of
patients as compared with 20% treated with placebo or
alternative [141]. Rifampin may be considered the first-
line therapy for pruritus, but this has not been the case
since its efficacy is not widely appreciated, and because of
certain untoward side effects and contraindications.
Rifampin is an enzyme inducer, hence the potential to
cause clinically relevant drug interactions should always
be considered, i.e. it may inactivate the effect of certain
antidepressants. Rifampin may cause hepatitis, hemolytic
anemia and renal dysfunction, usually within the initial
few weeks of therapy. Patients treated with rifampin need
to be monitored closely in this regard.
The precise mechanism of pruritus remains unclear. How-
ever, the efficacy of partial external biliary diversion, bil-
iary drainage and plasmapheresis for intractable pruritus
in patients with intrahepatic cholestasis suggest that pru-
ritogen(s) such as circulating endogeneous opioids are
present in both bile and blood [142-144], and increased
levels are reported in patients with PBC [145]. The efficacy
of naloxone, an opioid antagonist, for the pruritus of
chronic cholestasis supports this hypothesis and may be
one of the alternatives when the patients have failed other
treatments [146]. Symptoms suggestive of narcotic with-
drawal may develop in some patients, thus naloxone
should be introduced at very low dose and be built up
gradually, ideally by an experienced physician. Attention
Table 3: Screening and treatment of the complications of PBC
Osteoporosis Esophageal varices Hepatocellular carcinoma
Screening Method DEXA Endoscopy Ultrasound
Indication All patients Cirrhosis, Platelet count <200,000/
mm3
Cirrhosis, Portal hypertension
Interval Every 2 years Every 2 years (Every year, if grade 1 
varices)
Every 6 months
Treatment Indication All patients >Grade 2 varices Size, Number, Liver preservation 
dependant
Medication Calcium 1500 mg/d, Vitamin D 1000 
IU/d (+ Bisphosphanate, if 
osteoporotic)
β-blockers
Others Dairy products, Exercise, Sunlight Endoscopic ligation, Endoscopic 
sclerosing therapy
Radiofrequency ablation, Arterial 
embolization, Surgical resection, Liver 
transplantation
Table 2: Treatment of the symptoms of PBC
Pruritus 1st line Cholestyramine 4 g/d (before + after 
breakfast)
2nd line Rifampin 150 mg bid
3rd line Sertraline (anti-depressant)
4th line Naloxone, by an experienced 
physician
5th line Liver transplantation
Supportive UV light, Sunlight
Emergency Plasmapheresis
Raynauds 1st line Ca channel blockers
2nd line Alternative: prostacyclin and its 
derivatives, endothelin receptor 
antagonists and phosphodiesterase 
inhibitors
Sicca syndrome Dry eyes Artificial tears
Dry mouth Dental hygiene, dental visit every 3–6 
months
Dry vagina Vaginal lubricantsOrphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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to the chronic pain syndrome should be paid with long-
term use [147].
A recent randomized control trial has shown that sertra-
line (75–100 mg/day), a serotonine reuptake inhibitor,
seems to be an effective and well-tolerated treatment for
pruritus caused by chronic cholestasis. This suggests that
serotonergic pathways are important in the perception of
pruritus [148].
Plasmapheresis should be considered when treatment of
pruritus is urgently required, for example when the
patient is suicidal due to severe and uncontrollable pruri-
tus. Treatment with ultraviolet light may be beneficial,
particularly when the symptom worsens during the win-
ter.
Fatigue
Fatigue is one of the most common presenting complaints
in patients with PBC. There is no known treatment for
fatigue in PBC. However, complications such as hypothy-
roidism, anemia, depression or any other reasons for
fatigue have to be carefully excluded rather than assuming
PBC to be the cause, particularly as these complications
may be treatable. Many drugs such as UDCA [149],
cyclosporine [119], thalidomide [150] and antioxidants
[151] have been investigated previously but failed to show
any efficacy in controlling this debilitating symptom.
Even though the cause of fatigue in PBC remains unclear,
it may be related to dysfunction of either the cortico-
trophin-releasing hormone or serotonergic neurotrans-
mitter systems [152]. However, a randomized, controlled
crossover trial of ondansetron (a serotonin receptor antag-
onist) did not confer clinically significant fatigue reduc-
tion [153]. In a case series of 8 patients, methotrexate was
shown to be efficacious for fatigue in PBC [154]. More
recent data suggest a possibility that fatigue is associated
with excessive daytime somnolence and altered auto-
nomic function [155,156]. Open label modafinil therapy
(a central nervous system stimulant used to treat nar-
colepsy) was associated with improvement in excessive
daytime somnolence and associated fatigue in PBC [157].
Osteoporosis
Chronic cholestasis is associated with an increased risk of
osteopenia and osteoporosis. In the development of oste-
oporosis in PBC, there are two mechanisms that are com-
monly used to classify primary osteoporosis: "low-
turnover" with normal resorption but reduced synthesis
and slow mineralization of matrix and "high-turnover"
with increased resorption due to reduced osteoblast func-
tion or increased activity of osteoclast [158,159]. Com-
monly associated risk factors for primary osteoporosis
such as postmenopausal status, cigarette smoking and
alcohol consumption as well as malabsorption (co-exist-
ent celiac disease and/or jaundice) of calcium and vitamin
D may be also contributing factors in patients with PBC
[160,161]. Inherited predisposition to deficiency of vita-
min D associated with particular genetic polymorphisms
has been also reported [162]. However, whether patients
with PBC are at higher risk of developing osteoporosis
than general population is controversial [163,164]. Men-
opausal status and/or severity of liver disease may be inde-
pendent factors for osteoporosis development [165,166].
One study does suggest that osteoporosis is a feature of
PBC, especially in those patients who are older, thinner
and with more advanced liver disease [164]. Recently, it
has been confirmed in a population-based study that
there is a modest increase in both the absolute fracture
risks (12.5 per 1000 person-years for any fracture, and 1.9
per 1000 person-years and 3.4 per 1000 person-years for
hip fracture and for ulna/radius fracture, respectively) and
the relative fracture risks (approximately 2-fold increased)
in patients with PBC, with the excess risk similar in those
with more severe disease [167]. Additionally, bone frac-
ture post-OLT occurs due to the combination of preexist-
ing low bone mineral density and early post-OLT bone
loss [168]. Therefore, we should consider that all patients
with PBC are at risk of osteoporosis, and prophylactic and
therapeutic measures need to be undertaken. Screening
regularly for bone mineral density using non-invasive,
dual energy X-ray absorptiometry (DEXA scan), may iden-
tify bone changes prior to bone fractures.
It is difficult to prevent osteoporosis, but both calcium
supplements (1500 mg/d) and vitamin D (400–1200 IU/
d) are advised. Patients should be encouraged to take exer-
cise on regular basis and be in the sunlight to activate vita-
min D. The use of hormone replacement is controversial
for postmenopausal patients since it may provide protec-
tion against bone loss, but may worsen cholestasis [169].
Recently, alendronate has been demonstrated be more
effective than bisphosphonate for the treatment of oste-
oporosis in PBC [170]. A small pilot trial of vitamin K2 (a
fat-soluble vitamin that modulates bone metabolism sim-
ilarly to vitamin D) has shown the efficacy of vitamin K
for treatment of osteoporosis in PBC patients [171].
Portal hypertension and esophagogastric varices
Nodular regenerative hyperplasia (NRH) is a condition
characterized by hepatocytic nodules distributed through-
out the liver without perinodular fibrosis and caused by
occlusion of small portal veins in the portal tracts. In
patients with PBC, NRH may contribute to development
of non-cirrhotic portal hypertension [23]. We have shown
that patients with PBC and PSC that have a platelet count
<200,000/mm3, an albumin level <40 g/l, and a bilirubin
level >20 micromol/l should be screened for esophageal
varices [172]. Once patients are found to have moderate
to large esophageal varices, beta-blockers and/or endo-Orphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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scopic variceal ligation (EVL) should be instituted for pri-
mary prevention of variceal bleeding [173]. However,
nonselective beta-blockers are ineffective in preventing
the development of varices in unselected patients with cir-
rhosis [174]. There is a report showing earlier recurrence
of esophageal varices, following endoscopic therapy, in
patients with PBC compared with non-PBC patients
[175].
Hepatocellular carcinoma
One large retrospective study has shown that there is an
increased risk for development of hepatobiliary malig-
nancies in PBC [176]. Hepatocellular carcinoma (HCC) is
the most common malignancy in PBC, particularly in cir-
rhotic patients. When compared to the rate of HCC in
patients with chronic hepatitis C, the relative risks for
HCC were similar [177]. Older age, male sex and portal
hypertension and/or cirrhosis indicate higher likelihood
of HCC [178-180]. Therefore, screening for HCC, for
instance, ultrasound at 6 months interval, might be bene-
ficial in these patients.
Natural history and prognostic considerations
There are numerous reports on the natural history and
prognosis of PBC in terms of clinical, biochemical, histo-
logical and treatment response. Most of the published
data on survival in PBC indicate a poor prognosis but
these data were obtained from patients who were diag-
nosed more than 2–3 decades ago and never received
treatment [22]. It appears that, at present, the prognosis is
much better than the previously reported, probably
because patients are diagnosed at much earlier stage of the
disease and treatments are instituted earlier. The features
of patients diagnosed with PBC nowadays are different
from the days when this disease was first recognized and
described. Therefore, it is important that current patients
take this into account when they read outdated reports on
PBC!
Today, over 60% of the newly diagnosed cases are asymp-
tomatic [22], whereas just a few decades ago most of the
patients presented with jaundice. Although most patients
are diagnosed and initiated on treatment in the asympto-
matic phase, not all patients stay asymptomatic in long-
term follow-up. A population-based large cohort study of
patients with asymptomatic PBC has calculated the 1-year
incidence rate for developing fatigue, pruritus and com-
plications from portal hypertension to be 15%, 13% and
5%, respectively. The majority (80%) of asymptomatic
patients become symptomatic within 10 years and the
estimates for developing symptoms in 5 and 20 years are
50% and 95%, respectively [29]. Another large cohort of
patients with PBC has shown that the median survival or
liver transplantation referral from diagnosis was 9.3 years
[22]. Patients who were asymptomatic at diagnosis did
not live longer than their symptomatic counterparts but
the median age of this cohort at baseline was over 60 years
(63.1 and 61.8 years in asymptomatic and symptomatic
patients, respectively) [29]. Several other reports, based
on only a relatively small number of patient deaths during
the follow-up period, suggest that the survival of patients
asymptomatic at diagnosis falls significantly below than
that of gender- and age-matched control groups [181-
184]. However, these data are based on patients who had
been diagnosed decades ago, before the introduction of
UDCA. A substantial proportion of the asymptomatic
patients at diagnosis ultimately became symptomatic. The
estimated 10-year survival in asymptomatic patients with
PBC ranges from 57% to over 90% [14,181,185].
The only report of the natural history of histological
changes in PBC (without UDCA but with penicillamine or
placebo) has documented that the majority of patients
will progress histologically within 2 years. Histological
progression to cirrhosis in 4 years was observed in 31%,
50% and 68% of the patients in stage 1, stage 2 and stage
3 (according to Ludwig's classification) at entry, respec-
tively [186]. The incidence of cirrhosis after 5 years of
UDCA treatment was 4%, 12%, and 59% among patients
followed-up from stages 1, stage 2, and stage 3, respec-
tively [187]. UDCA appears to prevent the progression of
the disease, particularly if started in early-stage disease. A
recent encouraging report from Spain has shown that in
patients with an early-stage disease (stage 1 or stage 2), the
biochemical response to UDCA after 1 year is associated
with a similar survival to the matched control population
[107].
To date, no reliable way has been identified to predict
which patients will remain asymptomatic. An older study
of asymptomatic patients has suggested that the presence
of hepatomegaly, advanced histological stage or the pres-
ence of associated autoimmune disorders is strongly pre-
dictive of the subsequent development of PBC-related
symptoms (pruritus, jaundice, ascites or variceal bleed-
ing) [182,188], while a more recent study has not been
able to identify any prognostic variables that would dis-
tinguish patients who would become symptomatic from
those who would remain asymptomatic [181]. A recent
report has suggested that the presence of anti gp210 (one
of the antibodies to nuclear antigens) and especially when
in high titer may predict those patients who will have a
poor outcome [189], but this has been disputed [190].
Another recent study including patients with early-stage
disease has demonstrated that the independent predictive
factors of cirrhosis development were serum bilirubin
(>17 μmol/L), serum albumin (<38 g/L) and moderate to
severe lymphocytic piecemeal necrosis [187]. As an envi-
ronmental factor, smoking has been proven as a contrib-
uting risk factor for progression of the disease [76].Orphanet Journal of Rare Diseases 2008, 3:1 http://www.ojrd.com/content/3/1/1
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Classically, advanced age, elevated INR, jaundice, low
serum albumin, edema, ascites and advanced histological
stage are strongly correlated with median survival rates of
less than 5 years from time of diagnosis in symptomatic
patients. Serum total bilirubin is still one of the most reli-
able predictors for progression of the disease in PBC and
it plays a cardinal role in current mathematical models for
predicting survival, along with age, serum albumin, PT
and severity of edema [191].
The most common cause of death in patients with PBC
remains liver failure. Liver-related mortality has been
reported as 60% in symptomatic patients [22]. Asympto-
matic patients may also eventually die of liver failure
(20%) [29]. However, again, these numbers have been
retrieved from studies in large tertiary referral centers
before UDCA has been available, hence findings may not
always reflect current experience. Prospective cohort stud-
ies with observation for long periods with serial clinical,
biochemical and histological data may provide data that
helps to identify marker of disease progression in PBC.
Future direction
The true significance of UDCA on disease course and nat-
ural history remains controversial. Lack of any effect in
causing disease regression requires further studies on the
pathogenesis of this disease to identify new therapeutic
approaches. In this regard, the recent discovery of sponta-
neous animal models may allow us to better understand
the pathogenesis of PBC in humans. Further genetic
research may provide a bridge to clinical research, perhaps
indicating predictive markers of disease progression as
well as facilitating the basis for developing novel
approaches to therapy by throwing light on the pathogen-
esis of PBC. Only these may determine why standard
treatments for other autoimmune diseases are ineffective
in PBC. It is hoped that a genetic explanation for the dif-
ferent patterns of disease presentation in PBC might be
revealed and better targets for therapy still to be identified.
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